Follow The Filings

IMVT Immunovant Inc.

Health Care, filed as IMMUNOVANT INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3, sold by 2

  • 3 Owners
  • Max 1.0%
  • $226M
  • 1 add 2 reduce

In 2026 Q3 Farallon Capital Management added to Immunovant, while Nathan Fischel and David Einhorn trimmed.

Who owns this now

Largest portfolio weights among holders, up to 1.0% (Nathan Fischel, DAFNA Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 0.98%
  2. Farallon Capital Management Add 0.94%
  3. David Einhorn Reduce 0.07%

Who owns IMVT

Sorted by value, long equity only, as of 2026 Q3.

History
Farallon Capital Management 0.94% Add +11.5% 6,471,000 $219M History
Nathan Fischel, DAFNA Capital Management 0.98%, was 1.1% Reduce −9.4% 135,524 $4.6M History
David Einhorn, DME Capital Management 0.07%, was 0.10% Reduce −25.0% 70,140 $2.4M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IMVT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IMVT insider trades
  • $350M bought by 1 insider
  • $10.7M sold by 5 insiders outside a trading plan
  • $601K sold by 2 insiders under 10b5-1 plans
  1. Atul Pande Director
    Planned sale
    $108K 3,000 shares at $36.00 2.5% of stake
    Traded Nov 11 Filed Nov 12
  2. Atul Pande Director
    Planned sale
    $65K 1,500 shares at $43.27 1.3% of stake
    Traded Aug 28 Filed Aug 28
  3. Atul Pande Director
    Planned sale
    $60K 1,500 shares at $39.80 1.3% of stake
    Traded Jul 24 Filed Jul 24
  4. Melanie Gloria COO
    Sale
    $679K 17,714 shares at $38.31 7.3% of stake
    Traded Jun 26 Filed Jun 26
  5. Jay S. Stout Chief Technology Officer
    Sale
    $1.5M 40,000 shares at $38.31 16% of stake
    Traded Jun 26 Filed Jun 26
  6. Christopher Van Tuyl Chief Legal Officer
    Sale
    $683K 17,824 shares at $38.31 9% of stake
    Traded Jun 26 Filed Jun 26
  7. Tiago Girao CFO
    Sale
    $385K 10,000 shares at $38.46 3.9% of stake
    Traded Jun 26 Filed Jun 26
  8. Atul Pande Director
    Planned sale
    $57K 1,500 shares at $38.01 1.3% of stake
    Traded Jun 26 Filed Jun 26
  9. Atul Pande Director
    Planned sale
    $51K 1,500 shares at $34.02 1.3% of stake
    Traded Jun 15 Filed Jun 16
  10. Andrew J. Fromkin Director
    Sale
    $7.4M 221,951 shares at $33.51 75% of stake
    Traded May 28 Filed May 29
  11. Atul Pande Director
    Planned sale
    $192K 6,000 shares at $32.00 4.9% of stake
    Traded May 20 Filed May 20
  12. Robert Graham Susman Director
    Planned sale
    $68K 2,502 shares at $27.17 6.4% of stake
    Traded May 1 Filed May 1
  13. Roivant Sciences Ltd. Director
    Buy
    $350M 16.7M shares at $21.00 +17% to stake
    Traded Dec 12, 2025 Filed Dec 12, 2025

Also filed in the last 12 months, not counted as buying or selling: 45 sales to cover taxes, 15 option exercises, 11 stock grants, and 3 sales back to the company.

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
8-K 5.07
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A
8-K 2.02,9.01
10-K

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Net income -$210.96M -$259.34M -$413.84M -$505.61M

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $404.33M $665.77M $767.66M $948.82M
Total non-current assets * $1.5M $0.595M $8.56M $8.2M
Total assets $405.84M $666.36M $776.22M $957.01M
Total current liabilities $43.3M $48.61M $68.78M $104.42M
Total non-current liabilities * $47,000 $0.00 $0.00 $0.00
Total equity $362.49M $617.76M $707.45M $852.59M

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations -$188.19M -$214.23M -$375.87M -$407.31M
Cash from investing -$197,000 -$360,000 -$759,000 -$8,000
Cash from financing $70.88M $472.43M $454.49M $595.76M
Net change in cash -$117.28M $258.83M $78.61M $188.14M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf